Showing results (241-250 of 458) with videos related to

Sort By:
Pageof 46
Cell Death and Differentiation|June 3, 2017
MYCN amplified neuroblastoma requires the mRNA translation regulator eEF2 kinase to adapt to nutrient deprivationAlberto Delaidelli, Gian Luca Negri, Asad Jan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 21, 2022
Preclinical Development of [211At]meta- astatobenzylguanidine ([211At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for NeuroblastomaVandana Batra, Minu Samanta, Mehran Makvandi, et al.
The American Journal of Surgical Pathology|March 19, 2021
Stage 4S Neuroblastoma: Molecular, Histologic, and Immunohistochemical Characteristics and Presence of 2 Distinct Patterns of MYCN Protein Overexpression-A Report From the Children's Oncology GroupAsuka Kawano, Florette K Hazard, Bill Chiu, et al.
Pediatric Blood & Cancer|May 4, 2011
Initial testing (Stage 1) of AT13387, an HSP90 inhibitor, by the pediatric preclinical testing programMin H Kang, C Patrick Reynolds, Peter J Houghton, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 27, 2013
Semiquantitative mIBG scoring as a prognostic indicator in patients with stage 4 neuroblastoma: a report from the Children's oncology groupGregory A Yanik, Marguerite T Parisi, Barry L Shulkin, et al.
Pediatric Blood & Cancer|March 14, 2014
Initial testing (stage 1) of the investigational mTOR kinase inhibitor MLN0128 by the pediatric preclinical testing programMin H Kang, C Patrick Reynolds, John M Maris, et al.
Cancer Chemotherapy and Pharmacology|February 23, 2011
Phase I trial of lestaurtinib for children with refractory neuroblastoma: a new approaches to neuroblastoma therapy consortium studyJane E Minturn, Audrey E Evans, Judith G Villablanca, et al.
Pediatric Blood & Cancer|May 31, 2016
Initial Testing (Stage 1) of MK-8242-A Novel MDM2 Inhibitor-by the Pediatric Preclinical Testing ProgramMin H Kang, C Patrick Reynolds, E Anders Kolb, et al.
Pediatric Blood & Cancer|November 5, 2011
Initial testing (stage 1) of SGI-1776, a PIM1 kinase inhibitor, by the pediatric preclinical testing programVandana Batra, John M Maris, Min H Kang, et al.
Pediatric Blood & Cancer|March 26, 2014
Initial testing (stage 1) of the notch inhibitor PF-03084014, by the pediatric preclinical testing programHernan Carol, John M Maris, Min H Kang, et al.
Pageof 46